Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Infanrix Hib
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Infanrix Hib is a combination vaccine developed by GlaxoSmithKline. It provides active immunization against Diphtheria, Tetanus, Pertussis (whooping cough), and invasive diseases caused by *Haemophilus influenzae* type b (Hib). The vaccine is administered intramuscularly and works by stimulating the immune system to produce protective antibodies against the specific antigens from these pathogens.
- Brand names
- Infanrix Hib
- Other names
- DTPa-HibDTaP-Hib
02
Targets
PRN (Pertactin)FHA (Filamentous hemagglutinin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on Infanrix Hib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Infanrix Hib.